|
MTMR3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.34559999809269E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.09189999997206E-06 |
| Normal-vs-Stage2 |
4.210400E-04 |
| Normal-vs-Stage3 |
1.99020000479777E-08 |
| Normal-vs-Stage4 |
2.49279999975371E-08 |
| Stage1-vs-Stage2 |
7.572400E-01 |
| Stage1-vs-Stage3 |
1.016050E-01 |
| Stage1-vs-Stage4 |
1.634180E-02 |
| Stage2-vs-Stage3 |
4.694000E-01 |
| Stage2-vs-Stage4 |
1.966360E-01 |
| Stage3-vs-Stage4 |
4.157000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.22199999511119E-08 |
| Normal-vs-AfricanAmerican |
3.502700E-03 |
| Normal-vs-Asian |
3.104400E-03 |
| Caucasian-vs-AfricanAmerican |
7.826000E-01 |
| Caucasian-vs-Asian |
2.470400E-01 |
| AfricanAmerican-vs-Asian |
6.408400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.70039999980843E-07 |
| Normal-vs-Female |
3.17110000480625E-08 |
| Male-vs-Female |
7.986400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.91432999999686E-05 |
| Normal-vs-Age(41-60Yrs) |
2.2698000001764E-07 |
| Normal-vs-Age(61-80Yrs) |
2.92049995298527E-09 |
| Normal-vs-Age(81-100Yrs) |
2.943600E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.020800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.641500E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.191200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.483590E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.721200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.427600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.494300E-02 |
| Classical-VS-Follicular |
3.016900E-04 |
| Classical-VS-Other |
3.758600E-01 |
| Classical-VS-Normal |
4.83429999997842E-06 |
| Tall-VS-Follicular |
4.341200E-01 |
| Tall-VS-Other |
9.700600E-01 |
| Tall-VS-Normal |
1.69000000005415E-06 |
| Follicular-VS-Other |
7.584800E-01 |
| Follicular-VS-Normal |
8.52680004381767E-09 |
| Other-VS-Normal |
1.933970E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.56329999945193E-07 |
| Normal-vs-N1 |
1.77639999998647E-06 |
| N0-vs-N1 |
5.360400E-01 |
|
|
